Express News | Huapont Life Sciences: Elected Zhang Songshan as Director.

BreakingsMay 14 19:28

Huapont Life Sciences (002004.SZ): Huapont Pharmaceuticals received the pharmaceutical registration certificate for Lososofin Sodium Oral Solution.

Gelonghui, April 24 - Huapont Life Sciences (002004.SZ) announced that its wholly-owned subsidiary Chongqing Huapont Pharmaceutical Co., Ltd. (referred to as "Huapont Pharmaceutical") recently received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Loxoprofen Sodium Oral Solution. Loxoprofen Sodium Oral Solution is mainly used for rheumatoid arthritis, osteoarthritis, low back pain, periarthritis of the shoulder, neck-shoulder-wrist syndrome, toothache; pain relief and anti-inflammation after surgery, after trauma, and after tooth extraction; and acute upper respiratory tract inflammation (including acute upper respiratory tract inflammation accompanied by acute bronchitis).

Gelonghui FinanceApr 24 16:25

Huapont Life Sciences (002004.SZ): The company's direct export income from products to the USA accounts for less than 5% of total revenue.

Gelonghui reported on April 24 that Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that the revenue from products directly exported to the USA accounts for less than 5% of the total revenue, and most of these are currently listed as exempt Commodity categories. Therefore, the impact of the recent tariff increase on the company is relatively limited. At the same time, the company will closely monitor the trends in tariff policies, maintain good communication with clients, explore response strategies together, and strive to reduce negative impacts.

Gelonghui FinanceApr 24 15:07

Huapont Life Sciences (002004.SZ): The revenue from products directly exported to the USA accounts for less than 5% of total revenue.

Glory Finance reported on April 24 that Huapont Life Sciences (002004.SZ) stated on an interactive platform that the revenue from products directly exported to the USA accounts for less than 5% of total revenue, and most of these are currently classified as exempt Commodity categories. Therefore, the impact of the additional tariffs on the company is relatively limited. Meanwhile, the company will closely monitor the developments in tariff policies, maintain good communication with customers, jointly explore strategies, and strive to minimize negative impacts.

Gelonghui FinanceApr 24 15:07

Huabang Health: 2024 Annual Report Summary

SZSIApr 23 00:00 · Announcements

Huabang Health: Report for the first quarter of 2025

SZSIApr 23 00:00 · Announcements